Eur Rev Med Pharmacol Sci 2019; 23 (6): 2353-2359

DOI: 10.26355/eurrev_201903_17379

Long noncoding RNA DARS-AS1 acts as an oncogene by targeting miR-532-3p in ovarian cancer

K. Huang, W.-S. Fan, X.-Y. Fu, Y.-L. Li, Y.-G. Meng

Department of Obstetrics and Gynecology, Hanchuan People’s Hospital, Hanchuan, China. meng6512@vip.sina.com


OBJECTIVE: Ovarian cancer is one of the most ordinary malignant tumors. Recently, the role of long noncoding RNAs (lncRNAs) in tumor progression has caught attention of numerous researchers. In this research, lncRNA DARS-AS1 was studied to identify how it functions in the development of ovarian cancer.

PATIENTS AND METHODS: DARS-AS1 expression was detected by Real-time quantitative polymerase chain reaction (RT-qPCR) in ovarian cancer tissue samples. Moreover, functional experiments were conducted to detect the effect of DARS-AS1 on the proliferation and metastasis of ovarian cancer. In addition, the underlying mechanism was explored through luciferase assay and RNA immunoprecipitation (RIP) assay.

RESULTS: In this study, DARS-AS1 expression was remarkably higher in ovarian cancer tissues compared with that in adjacent ones. Cell proliferation was inhibited after DARS-AS1 silenced in ovarian cancer cells. Moreover, cell migration and invasion were also inhibited after DARS-AS1 silenced in ovarian cancer cells. Furthermore, results of luciferase assays and RIP assay showed that microRNA-532-3p (miR-532-3p) was a direct target of DARS-AS1 in ovarian cancer. The expression of miR-532-3p was upregulated after DARS-AS1 was knocked down.

CONCLUSIONS: Our study suggests that DARS-AS1 enhances cell proliferation and metastasis via sponging miR-532-3p in ovarian cancer.

Free PDF Download

To cite this article

K. Huang, W.-S. Fan, X.-Y. Fu, Y.-L. Li, Y.-G. Meng
Long noncoding RNA DARS-AS1 acts as an oncogene by targeting miR-532-3p in ovarian cancer

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 6
Pages: 2353-2359
DOI: 10.26355/eurrev_201903_17379